{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:15:31Z","timestamp":1758269731155},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3,27]]},"DOI":"10.1097\/qad.0b013e328325d115","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T15:26:01Z","timestamp":1242919561000},"page":"707-715","source":"Crossref","is-referenced-by-count":32,"title":["Effect of pulmonary tuberculosis on mortality in patients receiving HAART"],"prefix":"10.1097","volume":"23","author":[{"given":"Daniel","family":"Westreich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"MacPhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Van Rie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babatyi","family":"Malope-Kgokong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence","family":"Ive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Boulm\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Eron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Sanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-9-20210130","first-page":"225","article-title":"Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area","volume":"5","author":"Badri","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"R4-9-20210130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00002030-200101260-00002","article-title":"Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa","volume":"15","author":"Mukadi","year":"2001","journal-title":"AIDS"},{"key":"R5-9-20210130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1164\/ajrccm\/146.4.849","article-title":"Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality","volume":"146","author":"Nunn","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"R6-9-20210130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200201040-00010","article-title":"Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy","volume":"16","author":"Dean","year":"2002","journal-title":"AIDS"},{"key":"R7-9-20210130","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1086\/424676","article-title":"Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy","volume":"190","author":"Dheda","year":"2004","journal-title":"J Infect Dis"},{"key":"R8-9-20210130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","article-title":"Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy","volume":"43","author":"Manosuthi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-9-20210130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2796.2007.01795.x","article-title":"The TB pandemic: an old problem seeking new solutions","volume":"261","author":"Meya","year":"2007","journal-title":"J Intern Med"},{"key":"R10-9-20210130","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(02)08904-3","article-title":"Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study","volume":"359","author":"Badri","year":"2002","journal-title":"Lancet"},{"key":"R11-9-20210130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/01.aids.0000226959.87471.01","article-title":"Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study","volume":"20","author":"Etard","year":"2006","journal-title":"AIDS"},{"key":"R12-9-20210130","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1097\/01.aids.0000194802.89540.e1","article-title":"Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design","volume":"19","author":"Lawn","year":"2005","journal-title":"AIDS"},{"key":"R13-9-20210130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/QAD.0b013e328013f632","article-title":"Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda","volume":"21","author":"Moore","year":"2007","journal-title":"AIDS"},{"key":"R14-9-20210130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.296.7.782","article-title":"Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes","volume":"296","author":"Stringer","year":"2006","journal-title":"JAMA"},{"issue":"Suppl 1","key":"R17-9-20210130","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1086\/518655","article-title":"Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome","volume":"196","author":"McIlleron","year":"2007","journal-title":"J Infect Dis"},{"key":"R18-9-20210130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/aje\/kwm047","article-title":"Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model","volume":"166","author":"Cole","year":"2007","journal-title":"Am J Epidemiol"},{"key":"R19-9-20210130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"R20-9-20210130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"R21-9-20210130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3102\/10769986030001027","article-title":"Discrete-time survival mixture analysis","volume":"30","author":"Muth\u00e9n","year":"2005","journal-title":"J Educ Behav Stat"},{"key":"R23-9-20210130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/archinternmed.2007.10","article-title":"Effectiveness of antiretroviral treatment in a South African program: a cohort study","volume":"168","author":"Fairall","year":"2008","journal-title":"Arch Intern Med"},{"key":"R24-9-20210130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"key":"R25-9-20210130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R27-9-20210130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(06)68580-2","article-title":"Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment","volume":"367","author":"Ferradini","year":"2006","journal-title":"Lancet"},{"key":"R28-9-20210130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.aids.0000196177.65551.ea","article-title":"Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya","volume":"20","author":"Wools-Kaloustian","year":"2006","journal-title":"AIDS"},{"key":"R29-9-20210130","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1097\/01.aids.0000189866.67182.f7","article-title":"Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols","volume":"19","author":"Gandhi","year":"2005","journal-title":"AIDS"},{"key":"R30-9-20210130","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1128\/JCM.02411-05","article-title":"Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis","volume":"44","author":"Tsiouris","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R31-9-20210130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.200709-1311PP","article-title":"Immune reconstitution and \u2018unmasking\u2019 of tuberculosis during antiretroviral therapy","volume":"177","author":"Lawn","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-9-20210130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/QAD.0b013e3282f4a607","article-title":"Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study","volume":"22","author":"Murdoch","year":"2008","journal-title":"AIDS"},{"key":"R33-9-20210130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","article-title":"Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin","volume":"9","author":"Manosuthi","year":"2008","journal-title":"HIV Med"},{"key":"R34-9-20210130","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/01.aids.0000183630.27665.30","article-title":"Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin","volume":"19","author":"Manosuthi","year":"2005","journal-title":"AIDS"},{"key":"R35-9-20210130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"R36-9-20210130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J Epidemiol Community Health"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-200903270-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:07:53Z","timestamp":1618038473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200903270-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328325d115","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3,27]]}}}